Immune cells and pancreatic beta-cells

The interaction between immune cells and pancreatic beta-cells is the central pathological axis in Type 1 Diabetes (T1D). In this autoimmune process, various immune subsets, including CD4+ and CD8+ T-cells, B-cells, and macrophages, infiltrate the pancreatic islets (a process known as insulitis) and selectively destroy insulin-producing beta-cells (Atkinson et al., 2014). This destruction leads to absolute insulin deficiency and chronic hyperglycemia, requiring lifelong exogenous insulin replacement (DiMeglio et al., 2018). Therapeutic strategies targeting this interface aim to arrest the autoimmune attack, preserve remaining beta-cell mass, and promote immune tolerance (Roep et al., 2021). While not a single molecular target, this cellular interaction is the focus of immunotherapies such as anti-CD3 monoclonal antibodies (e.g., Teplizumab), which modulate T-cell responses to protect beta-cell function (Herold et al., 2019). Monitoring this interaction often involves measuring C-peptide levels as a proxy for beta-cell survival and the presence of islet-specific autoantibodies (Insel et al., 2015). Current research also explores the role of the beta-cell itself in signaling to the immune system, suggesting that beta-cell stress may trigger or exacerbate the initial autoimmune response (Mallone & Eizirik, 2020).

Other names

Beta-cell-immune system axisPancreatic islet-immune cell interactionInsulitis complexIslet-infiltrating lymphocytes

Inhibition of T-cell activation, depletion of B-cells, or modulation of cytokine signaling to prevent the autoimmune destruction of pancreatic beta-cells and preserve endogenous insulin production.